




### **COVID**

e malattie infettive stagionali

# COVID 19 e danni al SNC: Focus sulle Patologie Neurodegenerative

Giuseppe Neri Neurologo e Psichiatra
Past-President SNO , Società Neurologi Ospedalieri







#### Pathophysiology of CNS Involvement with SARS-CoV-2 **psych** scene SARS-CoV-2 INVASION Direct infection injury Hypoxic injury ACE2 Immune injury Hypercoagulability Haematogenous Neural pathway pathway Anaerobic metabolism SIRS Elevated D-dimer Myeloid cell trafficking Demyelination Cytokine release Neuroinflammation Endothelial damage in BBB BBB = Blood brain barrier ACE2 = Angiotensin-converting enzyme 2 SIRS = Systemic inflammatory response syndrome


Adapted and modified from Wu, Y., Xu, X., Chen, Z., Duan, J., Hashimoto, K., Yang, L., ... & Yang, C. (2020). Nervous system involvement after infection with COVID-19 and other coronaviruses. Brain, Behavior, and Immunity.


Viral encephalitis


Acute cerebrovascular disease

Infectious toxic encephalopathy











SuCs assist ORNs with odorant processing and help to maintain the cilia of ORNs

SuC Mucus cilia Odorant Coronavirus


It is not yet known whether the virus can transfer from SuCs to ORNs.

The virus infects
SuCs, because they
express the virus
entry proteins, ACE2
and TMPRSS2,
causing death of SuCs






#### **UCDAVIS**



1. SARS-CoV-2 binds to ACE2 receptors on microglia and

astrocytes.

- 2. This initiates an increase in cytokines.
- 3. An overexpression of cytokines leads to a "cytokine storm" that contributes to patients' neurological symptoms.
- 4. These lead to the underlying mechanisms of the patient's symptomology.







FIGURE 2 | Representative images of ACE2 expression among brain regions. (A) Immunostaining of negative control for ACE2 in the anterior cingulate cortex (PTB270). Scale bar = 100 mm. (B) Immunostaining of ACE2 by Rabbit anti-ACE2 antibody in the anterior cingulate cortex (PTB270). Scale bar = 100 mm. The enlarged views were listed on the right. EC. endothelial cell; NC, non-vascular cell. (C-N) Representative images of ACE2 expression among brain regions in health control. Scale bar = 100 mm. (O)




#### Huan Cui1†, Si Su1†, Yan Cao1†, Chao Ma1,2\* and Wenying Qiu1\*

1 Department of Human Anatomy, Histology, and Embryology, Neuroscience Center, School of Basic Medicine, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China, 2 Chinese Institute for Brain Research, Beijing, China

BRIEF RESEARCH REPORT published : 25 June 2021 doi: 10.3389/fcell.2021.684874





### **Trends in Neurosciences**

Volume 43, Issue 6, June 2020, Pages 355-357



Science & Society

# Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and the Central Nervous System

Fernanda G. De Felice 1, 2, 3 × ⋈, Fernanda Tovar-Moll 4, 5, Jorge Moll 5, Douglas P. Munoz 2, Sergio T. Ferreira 1, 6

- Institute of Medical Biochemistry Leopoldo de Meis, Federal University of Rio de Janeiro, Rio de Janeiro, RJ 21941-902, Brazil
- <sup>2</sup> Centre for Neuroscience Studies, Queen's University, Kingston, ON K7L 3N6, Canada
- Department of Psychiatry, Queen's University, Kingston, ON K7L 3N6, Canada
- <sup>4</sup> Institute of Biomedical Sciences, Federal University of Rio de Janeiro, Rio de Janeiro, RJ 21941-902, Brazil
- <sup>5</sup> D'Or Institute for Research and Education (IDOR), Rio de Janeiro, RJ, Brazil
- Institute of Biophysics Carlos Chagas Filho, Federal University of Rio de Janeiro, Rio de Janeiro, RJ 21941-902, Brazil


Available online 21 April 2020, Version of Record 26 May 2020.

It is now established that SARS-CoV-2 affects the CNS.

The inflammatory response elicited in acute or chronic infection may trigger or accelerate early and subclinical mechanisms that underlie the earliest stages of neurodegenerative disorders.

Moreover, because findings in neurodegenerative diseases and other viral infections suggest that systemic inflammatory mediators may access the CNS and trigger damage via impaired BBB function, systemic inflammation triggered by SARS-CoV-2 infection may further contribute to neuroinflammatory processes and increase susceptibility to neurological syndromes.

CNS infections may thus promote the development of neurodegenerative disease in individuals already at risk.



Neurological Symptom	Proposed Mechanism	Acute or Chronic	Population of Patients
Headache	Neuroinflammation	Both	12%
Anosmia (Loss of Smell)	Neuroinflammation or Nerve Damage	Both	50-60%
Ageusia (Loss of Taste)	Neuroinflammation or Nerve Damage	Both	40%
Confusion - "Brain Fog"	Neuroinflammation or Low Oxygen	Both	30-80%
Stroke	NeuroInflammation or Low Oxygen	More Chronic	1.8-2%
Brain Hemorrhage	Neuroinflammation	More Chronic	up to 12%
Memory Loss	Follows Stroke or HPA axis alteration	Both	27-34%
Psychatric Disorder	Neuroinflammation, HPA axis alteration, unknown	More Chronic	5-8%
Fever	Inflammation	More Acute	80%



## Per molti decenni intorno al Neurologo è stata confezionata una immagine il cui connotato distintivo era dato da :

- ELEVATA ERUDIZIONE
- RAFFINATE ED APPROFONDITE COMPETENZE SCIENTIFICO-CLINICHE
- ELEGANTE E COMPLETO BAGAGLIO DI SEMEIOLOGIA CLINICA

a queste caratteristiche risultava INDISSOLUBILMENTE legata, <u>non senza la attiva</u>

<u>collaborazione dei Neurologi stessi</u>, l' immagine di disporre di


RISORSE TERAPEUTICHE INCISIVE MOLTO LIMITATE.

La conclusione spesso tratta dai Colleghi di altre discipline, dalle Direzioni Sanitarie e dalle Direzioni Generali, dagli Assessorati alla Sanità, dai decisori politici era:

"IL NEUROLOGO E' UN SOFISTICATO
POSSESSORE DI ELABORATI SISTEMI
DI CATEGORIZZAZIONE NOSOGRAFICA...
ma NON CURA EFFICACEMENTE E NON GUARISCE
SE NON UNA ESIGUA MINORANZA DEI PAZIENTI CHE TRATTA "



Daniel Pennac Des Chrétiens et des Mores, 1996





















Dopo inizio pandemia il tempo medio di arrivo in Ospedale dei pazienti con Accidente Cerebrovascolare acuto è passato da 96 a 176 minuti rispetto all'esordio dei sintomi

Nello studio policentrico SNO sulle Neurologie Ospedaliere la incidenza della S. di Guillain- Barré è aumentata, dall'esordio della pandemia, del 300 %



Review Article

#### EUROPEAN Stroke Journal

#### Stroke care in Italy: An overview of strategies to manage acute stroke in COVID-19 time

European Stroke Journal 2020, Vol. 5(3) 222–229 © European Stroke Organisation 2020 Article reuse guidelines: sagepub.com/journals-permissions DOI: 10.1177/2396987320942622 journals.sagepub.com/home/eso

(\$)SAGE

Marialuisa Zedde<sup>1</sup>, Francesca Romana Pezzella<sup>2</sup>, Maurizio Paciaroni<sup>3</sup>, Francesco Corea<sup>4</sup>, Nicoletta Reale<sup>5</sup>, Danilo Toni<sup>6</sup> and Valeria Caso<sup>3</sup>

#### Abstract

Purpose: To analyse structural and non-structural modifications of acute stroke care pathways undertaken at health-care institutions across the regions of Italy due to the coronavirus disease 2019 (COVID-19) pandemic.

**Methods:** Research on National decrees specific for the pandemic was carried out. The stroke pathways of four Italian regions from North to South, such as Lombardy, Veneto, Lazio and Campania, were analysed before and after the pandemic outbreak.

Findings: On 29 February 2020, the Italian Minister of Health issued national guidelines on how to address the COVID-19 emergency. Stroke management was affected and required changes, basically resulting in the need to prioritise the ongoing COVID-19 emergency. In the most affected regions, the closure of departments and hospitals led to a complete reorganisation of previously functioning stroke networks. With the closure of several Stroke Units and Stroke Centres, the transportation time to hospital lengthened significantly, especially for the outlying populations.

**Discussion:** The COVID-19 pandemic outbreak has been spreading rapidly in Italy and placing an overwhelming burden on healthcare systems. In response to this, political and healthcare decision-makers worked together to develop and implement efforts to sustain the national healthcare system while fighting the pandemic. Stroke care pathways changed during the pandemic and different organisational models were applied in the most affected regions.

Conclusions: Stroke treatment pathways will need to be redesigned so to guarantee that severe and acute disease patients do not lose their rights to the access and delivery of care during the COVID-19 pandemics.

#### Keywords

Stroke, stroke management, COVID-19, pandemic, Italy

Date received: 30 April 2020; accepted: 18 June 2020

# ACCESSI IN PRONTO SOCCORSO per ACCIDENTE CEREBROVASCOLARE ACUTO da Marzo 2020 in avanti

- 57,5 % = 112.452 pazienti non trattati o trattati non adeguatamente

RITARDO NELL'ARRIVO in P.S. degli ICTUS: da 90 a 180 minuti

PAZIENTI ELIGIBILI AL TRATTAMENTO TROMBOLITICO: - 34 %

**TROMBOLISI Endovenose per ICTUS: - 26 %** 

**TROMBECTOMIE ENDOVASCOLARI ARTERIOSE PRIMARIE: -41%** 



**MORTALITA' INTRA-OSPEDALIERA: + 22%** 

MORTALITA' a 30 GIORNI: + 31 %

# MORTI POTENZIALMENTE EVITABILI PER ICTUS da MARZO 2020 :

ECCESSO MORTI epoca POST COVID: INTRA-OSPEDALE: 9178
ECCESSO MORTI epoca POST-COVID COVID: A 30 GIORNI: 1012

www.gregadura.com

## Dal 1 MARZO 2020, data convenzionale di inizio della PANDEMIA COVID in ITALIA


Abbiamo perso 9178 persone in più per accidenti cerebrovascolari acuti rispetto a Marzo- Novembre 2019


502 morti per ictus in più ogni mese, 32 al mese in più nella area di Roma Capitale


E' ragionevole presumere che almeno altri 7000 pazienti siano deceduti a casa non essendo mai stati portati, causa Covid, in Ospedale

















### INFEZIONI del S. N. C.

# Infezioni del sistema nervoso centrale

- Meningite→ processo infiammatorio con interessamento delle leptomeningi
- Encefalite → processo infiammatorio con interessamento del parenchima cerebrale
- meningoencefalite → processo infiammatorio con interessamento delle leptomeningi e del parenchima cerebrale
- Encefalomielite → infezione del parenchima cerebrale e del midollo spinale
- Ascesso cerebrale → infezione focale (occupante spazio)

## Interessamento del SISTEMA NERVOSO Centrale e Periferico in corso di INFEZIONI da AGENTI TRASMISSIBILI

**BATTERI** 

**VIRUS** 

**Agenti Trasmissibili Non Convenzionali** 

PRIONI

**Encefalopatie Spongiose Subacute Trasmmissibili** Malattia di Creutzfeldt – Jakob

New-Variant-CJD da BSE (c.d. "Mucca Pazza)

# **RETE delle NEUROLOGIE OSPEDALIERE OSPEDALIERE ROMANE SAN CAMILLO**

**SAN FILIPPO** 

**SPALLANZANI** 


## **SAN FILIPPO NERI**

**Prof. Alberto EDERLI** 

SAN CAMILLO
Prof. Giovanni ALEMA'

**SPALLANZANI** 

**Prof. Giuseppe VISCO** 





JOURNAL ARTICLE

### The AIDS Dementia Complex

Richard W. Price and Bruce J. Brew

The Journal of Infectious Diseases

Vol. 158, No. 5 (Nov., 1988), pp. 1079-1083 (5 pages)

Published By: Oxford University Press

https://www.jstor.org/stable/30136610

Cite this Item

Read and download Log in through your school or library Alternate access options
For independent researchers



#### Abstract

Note from Dr. Merle A. Sande - Progressive dementia has been recognized as a complication of human immunodeficiency virus infection almost since the beginning of the epidemic. To many infectious diseases clinicians, however, the AIDS dementia complex remains ambiguous, and the clinical approach to this problem is less clearly defined than that for other infection-associated syndromes. Dr. Richard W. Price and his colleagues at Memorial Sloa Kettering Cancer Center have, to a large extent, been responsible for defining this entity. In this AIDS Commentary the present their views of the current state of knowledge regarding the etiology, clinical presentation, and diagnostic and ther apeutic approaches to the AIDS dementia complex.





ORIGINAL RESEARCH

# Guillain-Barré syndrome and COVID-19: an observational multicentre study from two Italian hotspot regions

Massimiliano Filosto , <sup>1</sup> Stefano Cotti Piccinelli , <sup>2</sup> Stefano Gazzina, <sup>3</sup> Camillo Foresti, <sup>4</sup> Barbara Frigeni, <sup>4</sup> Maria Cristina Servalli, <sup>4</sup> Maria Sessa, <sup>4</sup> Giuseppe Cosentino, <sup>5</sup> Enrico Marchioni, <sup>6</sup> Sabrina Ravaglia, <sup>5</sup> Chiara Briani , <sup>7</sup> Francesca Castellani, <sup>7</sup> Gabriella Zara, <sup>7</sup> Francesca Bianchi, <sup>8</sup> Ubaldo Del Carro, <sup>8</sup> Raffaella Fazio, <sup>8</sup> Massimo Filippi , <sup>8</sup> Eugenio Magni, <sup>9</sup> Giuseppe Natalini, <sup>10</sup> Francesco Palmerini, <sup>9</sup> Anna Maria Perotti, <sup>9</sup> Andrea Bellomo, <sup>11</sup> Maurizio Osio, <sup>12</sup> Giuseppe Scopelliti , <sup>11</sup> Marinella Carpo, <sup>13</sup> Andrea Rasera, <sup>14</sup> Giovanna Squintani, <sup>14</sup> Pietro Emiliano Doneddu, <sup>15</sup> Valeria Bertasi, <sup>16</sup> Maria Sofia Cotelli, <sup>16</sup> Laura Bertolasi, <sup>17</sup> Gian Maria Fabrizi , <sup>17</sup> Sergio Ferrari , <sup>17</sup> Federico Ranieri , <sup>17</sup> Francesca Caprioli, <sup>18</sup> Elena Grappa, <sup>19</sup> Laura Broglio, <sup>3</sup> Giovanni De Maria, <sup>3</sup> Ugo Leggio, <sup>3</sup> Loris Poli, <sup>20</sup> Frank Rasulo, <sup>21</sup> Nicola Latronico, <sup>21</sup> Eduardo Nobile-Orazio , <sup>15</sup> Alessandro Padovani, <sup>2</sup> Antonino Uncini , <sup>22</sup>

► Additional material is published online only. To view, please visit the journal online (http://dx.doi.org/10.1136/ jnnp-2020-324837).

For numbered affiliations see end of article.

#### Correspondence to

Prof. Massimiliano Filosto, Department of Clinical and Experimental Sciences, University of Brescia; Unit of Neurology, ASST Spedali Civili; NeMO-Brescia Clinical Center for Neuromuscular Diseases, Brescia, Italy; massimiliano. filosto@unibs it

AP and AU contributed equally to the study and share senior authorship.

Received 14 August 2020 Revised 17 October 2020 Accepted 17 October 2020

#### **ABSTRACT**

**Objective** Single cases and small series of Guillain-Barré syndrome (GBS) have been reported during the SARS-CoV-2 outbreak worldwide. We evaluated incidence and clinical features of GBS in a cohort of patients from two regions of northern Italy with the highest number of patients with COVID-19.

**Methods** GBS cases diagnosed in 12 referral hospitals from Lombardy and Veneto in March and April 2020 were retrospectively collected. As a control population, GBS diagnosed in March and April 2019 in the same hospitals were considered.


Results Incidence of GBS in March and April 2020 was 0.202/100 000/month (estimated rate 2.43/100 000/year) vs 0.077/100 000/month (estimated rate 0.93/100 000/year) in the same months of 2019 with a 2.6-fold increase. Estimated incidence of GBS in COVID-19-positive patients was 47.9/100 000 and in the COVID-19-positive hospitalised patients was 236/100 000. COVID-19-positive patients with GBS, when compared with COVID-19-negative subjects, showed lower MBC sum score (26.3+18.3 vs 41.4+14.8

#### INTRODUCTION

In December 2019, Wuhan in China became the centre of an outbreak of pneumonia caused by a novel coronavirus named SARS-CoV-2.1 COVID-19 rapidly spread all over the world, acquiring the characteristics of a pandemic, and since February 2020, it has been spreading in Italy, particularly in the Lombardy and Veneto regions.2 With the increasing understanding of the disease, many nonpulmonary symptoms were recognised, including neurological complications such as acute cerebrovascular diseases, seizures, meningitis, encephalitis and skeletal muscle involvement.3-5 From 1 April to 30 June 2020, 42 patients with SARS-CoV-2 infection and Guillain-Barré syndrome (GBS) have been reported mostly from Europe, and the number of cases is increasing weekly, suggesting a possible association.6

Nowadays, GBS is considered a diagnostic umbrella including a number of related autoimmune polyneuropathies classified in variants and subtypes.<sup>7 8</sup> On the basis of electrophysiological

# CENTRAL ILLUSTRATION: Changes in the Rate of Cause-Specific Cardiovascular Hospitalization During the COVID-19 Pandemic



Bhatt, A.S. et al. J Am Coll Cardiol. 2020;76(3):280-8.



## NEUROLOGÍA



www.elsevier.es/neurologia

#### ORIGINAL ARTICLE

# Impact of the COVID-19 pandemic on the organisation of stroke care. Madrid Stroke Care Plan\*



- B. Fuentes a,\*, M. Alonso de Leciñana a, P. Calleja-Castaño b, J. Carneado-Ruiz c,
- J. Egido-Herrero<sup>d</sup>, A. Gil-Núñez<sup>e</sup>, J. Masjuán-Vallejo<sup>f</sup>, J. Vivancos-Mora<sup>g</sup>,
- J. Rodríguez-Pardo<sup>a</sup>, N. Riera-López<sup>h</sup>, Á. Ximénez-Carrillo<sup>g</sup>, A. Cruz-Culebras<sup>f</sup>,
- C. Gómez-Escalonilla<sup>d</sup>, E. Díez-Tejedor<sup>a</sup>, on behalf of the hospitals participating in the Madrid Stroke Care Plan

<sup>&</sup>lt;sup>a</sup> Servicio de Neurología y Centro de Ictus, Hospital Universitario La Paz, Universidad Autónoma de Madrid, Instituto de Investigación IdiPAZ, Madrid, Spain

<sup>&</sup>lt;sup>b</sup> Servicio de Neurología, Hospital Universitario 12 de Octubre, Universidad Complutense de Madrid, Madrid, Spain

c Servicio de Neurología, Hospital Universitario Puerta de Hierro, Universidad Autónoma de Madrid, Madrid, Spain

<sup>&</sup>lt;sup>d</sup> Servicio de Neurología, Hospital Clínico Universitario San Carlos, Universidad Complutense de Madrid, Madrid, Spain

e Servicio de Neurología, Hospital Universitario Gregorio Marañón, Universidad Complutense de Madrid, Madrid, Spain

<sup>&</sup>lt;sup>f</sup> Servicio de Neurología, Hospital Universitario Ramón y Cajal, Universidad de Alcalá de Henares, Alcalá de Henares (Madrid), Spain


<sup>&</sup>lt;sup>9</sup> Servicio de Neurología, Hospital Universitario de La Princesa, Universidad Autónoma de Madrid, Madrid, Spain

h Servicio de Urgencias Médicas de Madrid, SUMMA-112, Madrid, Spain


### 

REGIONS	POPULATION	IVT centers	IVT treatments	EVT centers	EVT treatments
Liguria	1,575,000	10	571	2	191
Friuli VG	1,223,000	3	426	2	88
Alto Adige	511,750	1	172	1	76
Trentino	534,405	1	161	1	2
Abruzzo	1,328,000	7	401	4	87
Veneto	4,925,000	22 <mark>(22)</mark>	1,485	6 (6)	360
Tuscany	3,753,000	22	1,129	3	395
Emilia Romagna	4,451,000	14 (12)	1,264	5 ( <del>5</del> )	585
Marche	1,551,000	7	365	1	82
Umbria	894,762	5	221	2	49
Piedmont	4,424,000	24	1,091	5	343
Sardinia	1,663,000	3	381	3	135
Lombardy	10,000,000	38 (8)	1,805	8 (6)	843
Lazio	5,882,000	20 (20)	1,049	7 (7)	476
Valle d'Aosta	128,298	1	20	1	14
Calabria	1,973,000	5	307	3	96
Sicily	5,082,000	17	696	3	163
Puglia	4,087,000	9	526	4	191
Basilicata	574,782	2	43	0	0
Campania	5,869,000	8 (8)	356	2 (2)	167
Molise	314,725	1	0	0	0
Totale	60,744,722	220	12,469	63	4,343











oltre a promuovere e organizzare conferenze, seminari, dibattiti, corsi di aggiornamento e di approfondimento,

### l'Associazione Culturale Anemos organizza:

- \_mostre, manifestazioni e visite anche di carattere artistico, sociale e umanitario;
- \_favorisce la nascita e l'operatività di gruppi di studio e di ricerca;
- \_promuove e gestisce biblioteche;
- \_realizza attività editoriali sia cartacee sia audiovisive;
- \_svolge attività di solidarietà internazionale organizzando viaggi di studio, missioni all'estero, gemellaggi e partnership nella realizzazione di opere, impianti, strutture e attività finalizzate alla crescita e sostentamento dei paesi in via di sviluppo.



Marco RUINI



